Tag: immunotherapy

Aimmune + Xencor

Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development...

“In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune’s global leadership in the evolving therapeutic landscape of food allergy treatments.”
Peanut Allergy Vaccine

Allergy Therapeutics Publishes Encouraging New Data for Peanut Allergy Vaccine Candidate

"This study indicates a paradigm shift by addressing peanut allergy via a vaccination concept instead of classic desensitisation..."
Viaskin Peanut

DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut...

If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.
Patient Undergoing SLIT

New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and...

UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.
FARE Reponse to ICER Report

Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies

FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
AAFA Reponse to ICER Report

Asthma and Allergy Foundation of America Responds to Premature ICER Review...

The AAFA addresses concerns regarding the Final Evidence Report released by the ICER.
AAFA Press Release Regarding ICER Review

Asthma and Allergy Foundation of America Elevates Patient Voice in ICER...

Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
Dr Kari Nadeau

Must Hear: Interview with Stanford Immunologist Dr Kari Nadeau – Defeating...

Dr Kari Nadeau, who runs the Sean Parker Center for Allergy and Asthma Research at Stanford University, takes us on a tour...
Researchers

Phase I Trial for New Peanut Allergy Immunotherapy Results in No...

Research details phase one study of peptide-based immunotherapy, which is designed to remove risks of acute reactions during treatment.
Vedanta Immunomodulator

Company Developing Microbiome-Derived Food Allergy Therapy Raises $27 Million

Product candidate being developed may safely induce permanent tolerance to food allergens.